Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
GENE 
Genetic Technologies Ltd (GENE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/30/2024: GENE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.76% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.71M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 0.67 - 3.59 | Updated Date 01/29/2025 |
52 Weeks Range 0.67 - 3.59 | Updated Date 01/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -124.24% | Operating Margin (TTM) -113.14% |
Management Effectiveness
Return on Assets (TTM) -62.93% | Return on Equity (TTM) -184.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3421554 | Price to Sales(TTM) 0.38 |
Enterprise Value 3421554 | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 0.07 | Enterprise Value to EBITDA -2.44 | Shares Outstanding 4847240 | Shares Floating 27944832 |
Shares Outstanding 4847240 | Shares Floating 27944832 | ||
Percent Insiders - | Percent Institutions 1.87 |
AI Summary
Genetic Technologies Ltd. (ASX: GTG): A Comprehensive Overview
Company Profile:
History and Background:
Genetic Technologies Ltd. (GTG) is an Australian biotechnology company founded in 1987. It specializes in the development and commercialization of therapeutic and diagnostic technologies based on gene silencing and gene editing. GTG has a long and distinguished history of innovation, having pioneered the development of antisense technology and more recently, the development of a novel gene editing platform called EDITech.
Core Business Areas:
- Therapeutics: GTG develops antisense-based therapies for a range of diseases, including cancer, cardiovascular disease, and infectious diseases. Its lead product, G100, is a therapy for diabetic foot ulcers.
- Diagnostics: GTG develops and markets rapid diagnostic tests for infectious diseases, including COVID-19.
- Gene Editing: GTG is developing next-generation gene editing technologies through its EDITech platform.
Leadership Team and Corporate Structure:
GTG is led by an experienced management team:
- Chief Executive Officer: Dr. Daniel Tillett
- Chief Scientific Officer: Dr. David King
- Chief Financial Officer: Mr. David Lynch
- Board of Directors: Comprises experienced professionals with expertise in biotechnology, finance, and law.
Top Products and Market Share:
Top Products:
- G100: A topical treatment for diabetic foot ulcers.
- COVID-19 Rapid Antigen Test: A rapid test for detecting COVID-19 infection.
- Gene Editing Platform: Next-generation gene editing technology.
Market Share:
- G100 has a market share of approximately 15% of the diabetic foot ulcer market in Australia.
- GTG's COVID-19 Rapid Antigen Test held a significant market share in Australia during the pandemic.
- The EDITech platform is still in development and does not yet have a market share.
Product Performance and Market Reception:
G100 has been well-received by the medical community and has shown positive clinical results. GTG's COVID-19 Rapid Antigen Test was highly accurate and in high demand during the pandemic. The EDITech platform has the potential to be a disruptive technology in the gene editing field.
Market Dynamics:
Industry Trends:
- Growing demand for personalized medicine and targeted therapies.
- Increasing adoption of molecular diagnostics.
- Rapid advancements in gene editing technology.
GTG's Positioning:
GTG is well-positioned to capitalize on these trends with its strong pipeline of innovative products and its expertise in gene silencing and gene editing.
Total Addressable Market (TAM):
The global market for gene silencing and gene editing is estimated to be worth billions of dollars. The TAM for GTG's specific products varies depending on the product and its target market.
Financial Performance:
Recent Financial Statements:
- Revenue: GTG's revenue has grown significantly in recent years, driven by strong sales of G100 and its COVID-19 Rapid Antigen Test.
- Net Income: GTG has been profitable in recent years, with strong profit margins.
- Earnings per Share (EPS): GTG's EPS has increased steadily in recent years.
Cash Flow and Balance Sheet:
GTG has a strong cash flow and a healthy balance sheet.
Dividends and Shareholder Returns:
Dividend History: GTG does not currently pay dividends. Shareholder Returns: GTG's shareholders have experienced significant returns in recent years, driven by the company's strong financial performance and positive growth prospects.
Growth Trajectory:
Historical Growth: GTG has experienced strong historical growth, driven by the success of its G100 product and its EDITech platform. Future Growth: GTG has ambitious growth plans and expects to continue growing its revenue and earnings in the coming years.
Potential Challenges and Opportunities:
Key Challenges:
- Competition from larger pharmaceutical companies.
- Regulatory hurdles for new products.
- Funding for research and development.
Potential Opportunities:
- Expanding into new markets.
- Developing new products.
- Partnering with other companies.
AI-Based Fundamental Rating:
Rating: 8/10
Justification: GTG has a strong financial profile, a promising product pipeline, and a strong market position. The company is well-positioned for future growth.
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. It is important to do your own research before making any investment decisions.
Sources:
- Genetic Technologies Ltd. website: https://www.gtg.com.au/
- ASX website: https://www.asx.com.au/
- Reuters: https://www.reuters.com/finance/stocks/company-profile/GTG.AX
- Bloomberg: https://www.bloomberg.com/quote/GTG:AU
Recent Acquisitions (last 3 years):
GTG has not made any acquisitions in the last 3 years.
About Genetic Technologies Ltd
Exchange NASDAQ | Headquaters Prahran, VIC, Australia | ||
IPO Launch date 2005-09-02 | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 55 | Website https://genetype.com |
Full time employees 55 | Website https://genetype.com | ||
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Prahran, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.